Regenstrief names Tierney CEO, president

William M. Tierney, MD, has been named president and CEO of the Regenstrief Institute. Pending approval by the Indiana University (IU) trustees, he also will serve as associate dean for clinical effectiveness research at the Indiana University School of Medicine in Indianapolis.

Tierney will assume his new positions in October when he takes the reins from Thomas S. Inui, MD, who will remain with the Indianapolis-based medical research organization.

A graduate of Indiana University and the IU School of Medicine and one of Regenstrief’s first post-graduate trainees, Tierney has spent his 30-year career as a physician-investigator at Regenstrief and the IU School of Medicine. According to the institute, Tierney studies the effects of computer-based interventions to improve healthcare quality and lower costs of healthcare delivery.

Tierney will step down from his current position as director of research for the IU-AMPATH Program in East Africa where, since 2002, he and IU colleagues have led a consortium of more than 15 North American universities performing research with Moi University in Western Kenya.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.